JP2007504812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504812A5 JP2007504812A5 JP2006525744A JP2006525744A JP2007504812A5 JP 2007504812 A5 JP2007504812 A5 JP 2007504812A5 JP 2006525744 A JP2006525744 A JP 2006525744A JP 2006525744 A JP2006525744 A JP 2006525744A JP 2007504812 A5 JP2007504812 A5 JP 2007504812A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- nos
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 102100022641 Coagulation factor IX Human genes 0.000 claims 4
- 108010076282 Factor IX Proteins 0.000 claims 4
- 229960004222 factor ix Drugs 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108010048049 Factor IXa Proteins 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 230000002947 procoagulating effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/661,366 US7297336B2 (en) | 2003-09-12 | 2003-09-12 | Factor IXa specific antibodies displaying factor VIIIa like activity |
| US10/661,366 | 2003-09-12 | ||
| PCT/EP2004/009975 WO2005025615A2 (en) | 2003-09-12 | 2004-09-07 | FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007504812A JP2007504812A (ja) | 2007-03-08 |
| JP2007504812A5 true JP2007504812A5 (cg-RX-API-DMAC7.html) | 2007-08-16 |
| JP4887148B2 JP4887148B2 (ja) | 2012-02-29 |
Family
ID=34273861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525744A Expired - Fee Related JP4887148B2 (ja) | 2003-09-12 | 2004-09-07 | 第ＶＩＩＩａ因子様活性を示す第ＩＸａ因子特異抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7297336B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1660536B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4887148B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE419277T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004271706B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2538895A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE602004018788D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2320665T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005025615A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| DK1876236T3 (da) * | 2005-04-08 | 2014-10-20 | Chugai Pharmaceutical Co Ltd | Antistof som funktionel erstatning for blodkoagulationsfaktor VIII |
| EP1760092A1 (en) * | 2005-08-26 | 2007-03-07 | Applied Research Systems ARS Holding N.V. | System for screening cells for high expression of a protein of interest |
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| EP4218801A3 (en) | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| PL2202245T3 (pl) | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
| CN103298937B (zh) | 2010-11-17 | 2016-05-25 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| KR102134305B1 (ko) * | 2012-09-28 | 2020-07-15 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고반응의 평가방법 |
| CN105764922B (zh) | 2013-09-27 | 2020-07-17 | 中外制药株式会社 | 多肽异源多聚体的制备方法 |
| CA2939293C (en) | 2014-03-11 | 2023-10-03 | The Board Of Trustees Of The Leland Standford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定ｆｖｉｉｉ的反應性之方法 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
| WO2017110980A1 (ja) | 2015-12-25 | 2017-06-29 | 中外製薬株式会社 | 増強された活性を有する抗体及びその改変方法 |
| US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
| MX2018012648A (es) | 2016-04-28 | 2019-01-30 | Chugai Pharmaceutical Co Ltd | Preparaciones que contienen anticuerpos. |
| BR112018073660A2 (pt) * | 2016-05-16 | 2019-02-19 | Baxalta Incorporated | anticorpos anti-fator ix pádua |
| ES3000618T3 (en) | 2016-09-06 | 2025-03-03 | Chugai Pharmaceutical Co Ltd | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
| KR20190052027A (ko) * | 2016-09-23 | 2019-05-15 | 씨에스엘 리미티드 | 응고 인자 결합 단백질 및 이의 용도 |
| AU2017363309A1 (en) * | 2016-11-23 | 2019-07-11 | Bioverativ Therapeutics Inc. | Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X |
| PE20191347A1 (es) | 2017-02-01 | 2019-09-30 | Novo Nordisk As | Anticuerpos procoagulantes |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| CN111108202B (zh) | 2017-09-29 | 2024-10-22 | 中外制药株式会社 | 具有凝血因子viii(fviii)辅因子功能替代活性的多特异性抗原结合分子及含有所述分子作为活性成分的药物制剂 |
| SG11202003833TA (en) | 2017-11-01 | 2020-05-28 | Chugai Pharmaceutical Co Ltd | Antibody variant and isoform with lowered biological activity |
| US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
| CA3113797A1 (en) * | 2018-08-01 | 2020-02-06 | Novo Nordisk A/S | Improved procoagulant antibodies |
| JP7530362B2 (ja) | 2018-12-21 | 2024-08-07 | カイマブ・リミテッド | 共通の軽鎖を有するＦＩＸａ×ＦＸ二重特異性抗体 |
| EP4097141A1 (en) | 2020-01-30 | 2022-12-07 | Novo Nordisk A/S | Bispecific factor viii mimetic antibodies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT368883B (de) | 1980-07-22 | 1982-11-25 | Immuno Ag | Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| CA2143125C (en) | 1992-08-27 | 2008-09-23 | Koenraad Mertens | Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein |
| DK128093D0 (da) | 1993-11-12 | 1993-11-12 | Novo Nordisk As | Hidtil ukendte forbindelser |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
| JP2002510321A (ja) | 1997-07-03 | 2002-04-02 | スミスクライン・ビーチャム・コーポレイション | 抗−第ＩＸ因子 Ｆａｂフラグメントの結晶構造およびペプチド模倣物デザインのための使用方法 |
| AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| CU23007A1 (es) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| BR0209177A (pt) * | 2001-05-03 | 2004-10-05 | Merck Patent Gmbh | Anticorpo especìfico a tumor recombinante e uso do mesmo |
-
2003
- 2003-09-12 US US10/661,366 patent/US7297336B2/en not_active Expired - Lifetime
-
2004
- 2004-09-07 ES ES04764918T patent/ES2320665T3/es not_active Expired - Lifetime
- 2004-09-07 CA CA002538895A patent/CA2538895A1/en not_active Abandoned
- 2004-09-07 JP JP2006525744A patent/JP4887148B2/ja not_active Expired - Fee Related
- 2004-09-07 AU AU2004271706A patent/AU2004271706B2/en not_active Expired
- 2004-09-07 DE DE602004018788T patent/DE602004018788D1/de not_active Expired - Lifetime
- 2004-09-07 WO PCT/EP2004/009975 patent/WO2005025615A2/en not_active Ceased
- 2004-09-07 EP EP04764918A patent/EP1660536B1/en not_active Expired - Lifetime
- 2004-09-07 AT AT04764918T patent/ATE419277T1/de active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007504812A5 (cg-RX-API-DMAC7.html) | ||
| US20220289858A1 (en) | Anti-cd40 antibodies and uses thereof | |
| RU2650767C2 (ru) | Интерлейкин-13-связывающие белки | |
| CN102421795B (zh) | 针对肌钙蛋白i的抗体及其使用方法 | |
| CN114539414B (zh) | 抗凝血因子xi抗体 | |
| JP2022036944A (ja) | Ｒｇｍ ａタンパク質に対するモノクローナル抗体及びその使用 | |
| JP2011527902A5 (cg-RX-API-DMAC7.html) | ||
| JP2008542278A5 (cg-RX-API-DMAC7.html) | ||
| US20130267688A1 (en) | Novel antibody structures derived from human germline sequences | |
| CN102076714A (zh) | 结合Aβ(1-42)球聚体的人源化抗体及其应用 | |
| CN105102480A (zh) | 催乳素受体结合蛋白及其用途 | |
| RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
| TW201124427A (en) | IL-1 binding proteins | |
| Roque-Navarro et al. | Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method | |
| JP2021101720A (ja) | 抗凝固因子ｘｉ抗体 | |
| JP2024105229A5 (cg-RX-API-DMAC7.html) | ||
| JP2010527939A5 (cg-RX-API-DMAC7.html) | ||
| JP2010501164A5 (cg-RX-API-DMAC7.html) | ||
| IL265350B2 (en) | Antibody specifically binding to il-17a and functional fragment thereof | |
| CN111492066A (zh) | 使用转录本进行抗体方向的方法及由其衍生的组合物 | |
| JP2005510201A5 (cg-RX-API-DMAC7.html) | ||
| CN110423278B (zh) | 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用 | |
| CN114656556A (zh) | 一种抗新型冠状病毒的全人源单克隆抗体及其应用 | |
| US7858089B2 (en) | Antibodies binding to the A2 domain of FVIII and inhibiting coagulation activity | |
| TW202039583A (zh) | 結合因子IXa及因子X的蛋白分子 |